| Literature DB >> 27983855 |
Ahu Yuan1,2,3, Wei Huan1, Xiang Liu1, Zhicheng Zhang1, Yifan Zhang1, Jinhui Wu1,2,3, Yiqiao Hu1,2,3.
Abstract
Nanocarriers like PEGylated liposomes have achieved enhanced drug accumulation in tumors and reduced systemic side effects, but failed to actively release the carried drug into cancer cells. To obtain improved therapeutic efficacy, we designed a novel liposome that was inserted by the amphiphilic agent PEG-IR780-C13 (PIC-Lipo) and encapsulated therapeutic agent doxorubicin (DOX), termed as DOX@PIC-Lipo. Upon NIR laser irradiation, the novel liposomes could generate hyperthermia and facilitate the release of encapsulated DOX from PIC-Lipo, which were confirmed by photothermal curves and the DOX release assay in vitro, respectively. In addition, the enhanced DOX release and sufficient hyperthermia have performed synergetic therapeutic efficacy both in vitro and in vivo. Therefore, DOX@PIC-Lipo might provide an active strategy to release the loaded drug for synergetic chemo-photothermal combined therapy.Entities:
Keywords: NIR light; activatable; chemo−photothermal therapy; doxorubicin; liposome
Mesh:
Substances:
Year: 2016 PMID: 27983855 DOI: 10.1021/acs.molpharmaceut.6b00820
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939